AR059647A1 - Antigenos vacunales quimericos contra el virus de la influenza aviar - Google Patents

Antigenos vacunales quimericos contra el virus de la influenza aviar

Info

Publication number
AR059647A1
AR059647A1 ARP070100807A ARP070100807A AR059647A1 AR 059647 A1 AR059647 A1 AR 059647A1 AR P070100807 A ARP070100807 A AR P070100807A AR P070100807 A ARP070100807 A AR P070100807A AR 059647 A1 AR059647 A1 AR 059647A1
Authority
AR
Argentina
Prior art keywords
chimeric
antigens
virus
vaccine
avian influenza
Prior art date
Application number
ARP070100807A
Other languages
English (en)
Inventor
Ramos Oliberto Sanchez
Alonso Jorge Roberto Toledo
Archer Damarys Diaz
Baile Nancy Elena Figueroa
Molto Maria Pilar Rodriguez
Nordelo Carlos Guiller Borroto
Original Assignee
Ct Ingenieria Genetica Biotech
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ct Ingenieria Genetica Biotech filed Critical Ct Ingenieria Genetica Biotech
Publication of AR059647A1 publication Critical patent/AR059647A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/145—Orthomyxoviridae, e.g. influenza virus
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/08—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses
    • C07K16/10—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from viruses from RNA viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/605—MHC molecules or ligands thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/64—Medicinal preparations containing antigens or antibodies characterised by the architecture of the carrier-antigen complex, e.g. repetition of carrier-antigen units
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/32—Fusion polypeptide fusions with soluble part of a cell surface receptor, "decoy receptors"
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/735—Fusion polypeptide containing domain for protein-protein interaction containing a domain for self-assembly, e.g. a viral coat protein (includes phage display)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/16011—Orthomyxoviridae
    • C12N2760/16111—Influenzavirus A, i.e. influenza A virus
    • C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Epidemiology (AREA)
  • Genetics & Genomics (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pulmonology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Oncology (AREA)
  • Cell Biology (AREA)
  • Toxicology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)

Abstract

La presente describe antígenos vacunales quiméricos contra el virus de la Influenza Aviar (lA). Dichos antígenos vacunales están basados en subunidades virales que están acopladas a moléculas proteicas estimuladoras del sistema inmune, tanto celular como humoral. Los antígenos quiméricos pueden ser producidos en sistemas de expresion que garantizan un correcto plegamiento tridimensional de las moléculas quiméricas que constituyen la base de la presente solicitud. Las composiciones vacunales que contienen dichos antígenos quiméricos inducen una respuesta inmune potente y temprana tanto en las aves como en los mamíferos vacunados, estimulando altos títulos de anticuerpos inhibidores de la hemaglutacion y una potente respuesta celular específica contra el antígeno viral. Los antígenos quiméricos, así como las composiciones vacunales resultantes son aplicables a la esfera de la salud humana y animal, como vacunas para uso preventivo. Reivindicacion 1: Antígeno vacunal quimérico contra el virus de la lA, caracterizado por contener el segmento extracelular de la HA de la envoltura del virus de la lA y el segmento extracelular de molécula CD154.
ARP070100807A 2006-02-28 2007-02-27 Antigenos vacunales quimericos contra el virus de la influenza aviar AR059647A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
CU20060051A CU23576A1 (es) 2006-02-28 2006-02-28 Antígenos vacunales quiméricos contra el virus de la influenza aviar

Publications (1)

Publication Number Publication Date
AR059647A1 true AR059647A1 (es) 2008-04-16

Family

ID=40130782

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP070100807A AR059647A1 (es) 2006-02-28 2007-02-27 Antigenos vacunales quimericos contra el virus de la influenza aviar

Country Status (14)

Country Link
US (1) US20090324644A1 (es)
EP (1) EP1997831A1 (es)
JP (1) JP2009528305A (es)
KR (1) KR20080113217A (es)
CN (1) CN101421302A (es)
AR (1) AR059647A1 (es)
AU (1) AU2007219571A1 (es)
BR (1) BRPI0708383A2 (es)
CA (1) CA2638832A1 (es)
CL (1) CL2007000526A1 (es)
CU (1) CU23576A1 (es)
MX (1) MX2008011143A (es)
RU (1) RU2008138535A (es)
WO (1) WO2007098718A1 (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3097926T (pt) * 2007-11-01 2020-01-08 Univ Guelph Composições e métodos de potenciação das respostas imunitárias frente a eimeria
JP2012525134A (ja) * 2009-04-30 2012-10-22 サイトス バイオテクノロジー アーゲー インフルエンザ赤血球凝集素の組成物とその使用
TW201738562A (zh) * 2009-05-28 2017-11-01 亞培生物股份有限公司 體外病原體檢驗技術
KR101262300B1 (ko) * 2009-10-06 2013-05-20 헬릭스 주식회사 형질전환 식물 유래의 고병원성 조류독감 바이러스 단백질 백신 및 그 제조방법
US9795661B2 (en) 2009-11-16 2017-10-24 The United States Of America As Represented By The Secretary Of The Navy TH1/TH2 polarizing vaccines
US10376571B2 (en) 2013-03-15 2019-08-13 The Board Of Trustees Of The University Of Arkansas Compositions and methods of enhancing immune responses to enteric pathogens
KR101582490B1 (ko) 2014-04-14 2016-01-19 아이디바이오 주식회사 인플루엔자 바이러스의 다중 아형에 대한 교차 면역반응을 형성하는 신규한 재조합 바이러스 백신
KR20230070521A (ko) 2016-05-03 2023-05-23 더 보드 오브 트러스티스 오브 더 유니버시티 오브 아칸소 면역자극 및 항원 폴리펩티드를 포함하는 효모 백신 벡터, 및 그를 이용하는 방법
KR101964044B1 (ko) * 2018-03-14 2019-04-02 인제대학교 산학협력단 재조합 아데노바이러스를 이용한 다가형 인플루엔자 생백신 플랫폼
CN112679586A (zh) * 2020-12-28 2021-04-20 乾元浩生物股份有限公司 H5、h7亚型禽流感病毒基因工程亚单位疫苗及其制备方法与应用
CN114106113B (zh) * 2021-11-13 2024-04-19 江苏南农高科技股份有限公司 一种表达猪细小病毒vp2蛋白的重组杆状病毒、制备方法及应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2370937T3 (es) 1993-09-13 2011-12-23 Protein Sciences Corporation Un método para producir vacunas antigripales polivalentes a base de hemaglutinina.
US5762939A (en) 1993-09-13 1998-06-09 Mg-Pmc, Llc Method for producing influenza hemagglutinin multivalent vaccines using baculovirus
US20020136722A1 (en) * 1997-06-18 2002-09-26 Heath Andrew William Vaccination method
CU23102A1 (es) * 2002-10-21 2005-12-20 Ct Ingenieria Genetica Biotech Método para la producción de proteínas recombinantes en la glándula mamaria de mamíferos no transgénicos
US9533036B2 (en) * 2005-11-07 2017-01-03 Microvax, Llc Methods for generating immune responses to influenza antigens with a secretable CD40L fusion protein

Also Published As

Publication number Publication date
KR20080113217A (ko) 2008-12-29
CA2638832A1 (en) 2007-09-07
RU2008138535A (ru) 2010-04-10
CL2007000526A1 (es) 2009-03-27
AU2007219571A1 (en) 2007-09-07
CN101421302A (zh) 2009-04-29
CU23576A1 (es) 2010-09-30
EP1997831A1 (en) 2008-12-03
BRPI0708383A2 (pt) 2011-05-24
JP2009528305A (ja) 2009-08-06
WO2007098718A1 (es) 2007-09-07
MX2008011143A (es) 2008-09-08
US20090324644A1 (en) 2009-12-31
WO2007098718A8 (es) 2008-12-18

Similar Documents

Publication Publication Date Title
AR059647A1 (es) Antigenos vacunales quimericos contra el virus de la influenza aviar
Krammer et al. Advances in the development of influenza virus vaccines
Kang et al. Virus-like particles as universal influenza vaccines
CY1118492T1 (el) Φαρμακοτεχνικες μορφες εμβολιου norovirus
Ghendon et al. Chitosan as an adjuvant for parenterally administered inactivated influenza vaccines
CR20180174A (es) Nuevos péptidos, combinaciones de péptidos y soportes para el uso en el tratamiento inmunoterapéutico de varios tipos de cáncer
CR10559A (es) Vacuna de influenza
Riedl et al. The novel adjuvant IC31® strongly improves influenza vaccine-specific cellular and humoral immune responses in young adult and aged mice
CY1113546T1 (el) Μικρορευστοποιημενα γαλακτωματα ελαιου σε νερο και συνθεσεις εμβολιων
CY1120430T1 (el) Ανασυνδυασμενες cdv συνθεσεις και χρησεις αυτων
CO6491045A2 (es) Composiciones de proteina f de virus sincitial respiratorio (rsv) y metodos para producir las mismas
AR072378A1 (es) Composicion inmunogenica que comprende una formulacion de adyuvante. composicion de vacuna. procedimiento. usos. metodos.
RU2013114980A (ru) Вакцинная композиция
BR112015023105A8 (pt) construto de imunógeno de peptídeo ab, seu uso, composição que o compreende, vacina de peptídeo para prevenção e imunoterapia de demência do tipo alzheimer e anticorpo.
BR112016004108A2 (pt) métodos para expressar uma molécula antigênica ou uma parte da mesma e para geração de uma resposta imune, composição farmacêutica, célula ou população de células, usos de uma população de células e de uma molécula antigênica, moléculas antigênica, agentes de fotossensibilização e ligante tlr e agente, produto, e, kit
Dabaghian et al. Vaccination with recombinant 4× M2e. HSP70c fusion protein as a universal vaccine candidate enhances both humoral and cell-mediated immune responses and decreases viral shedding against experimental challenge of H9N2 influenza in chickens
BRPI0707779B8 (pt) antígeno isolado, composição de vacina e método para produção de uma proteína antígeno
RU2013108067A (ru) Противогриппозная вакцина
BR112013029417A2 (pt) composições de vacina de matriz proteica incluindo policátions
AR059648A1 (es) Antigenos vacunales quimericos contra el virus de la peste porcina clasica
Shrestha et al. Canine zona pellucida glycoprotein-3: up-scaled production, immunization strategy and its outcome on fertility
PH12014501795A1 (en) Rota virus subunit vaccines and methods of making and use thereof
BR112012022059A8 (pt) Vacina de mucosa produtora de uma iga de mucosa antígenoespecífica e igg do sangue e método para produzir uma vacina de mucosa
JP6764408B2 (ja) Ｈ１ｎ１インフルエンザに対するコンピュータ最適化広反応性抗原の相乗的併用投与
AR082577A1 (es) Vacunas de virus varicela zoster inactivado, metodos de produccion y uso de las mismas

Legal Events

Date Code Title Description
FA Abandonment or withdrawal